

Francesco Sparano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3045697/publications.pdf>

Version: 2024-02-01

17
papers

127
citations

1478505

6
h-index

1372567

10
g-index

18
all docs

18
docs citations

18
times ranked

227
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Patient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review. <i>Supportive Care in Cancer</i> , 2018, 26, 2075-2090. | 2.2 | 21 |
| 2 | Investigating the impact of open label design on patient-reported outcome results in prostate cancer randomized controlled trials. <i>Cancer Medicine</i> , 2020, 9, 7363-7374. | 2.8 | 19 |
| 3 | Impact of Blinding on Patient-Reported Outcome Differences Between Treatment Arms in Cancer Randomized Controlled Trials. <i>Journal of the National Cancer Institute</i> , 2022, 114, 471-474. | 6.3 | 15 |
| 4 | Differences in Patient-Reported Outcomes That Are Most Frequently Detected in Randomized Controlled Trials in Patients With Solid Tumors: A Pooled Analysis of 229 Trials. <i>Value in Health</i> , 2020, 23, 666-673. | 0.3 | 13 |
| 5 | Harnessing the patient voice in prostate cancer research: Systematic review on the use of patient-reported outcomes in randomized controlled trials to support clinical decision-making. <i>Cancer Medicine</i> , 2020, 9, 4039-4058. | 2.8 | 11 |
| 6 | Patient-reported outcomes in randomised clinical trials of bladder cancer: an updated systematic review. <i>BMC Urology</i> , 2019, 19, 86. | 1.4 | 10 |
| 7 | Patient-Reported Outcomes in Randomized Controlled Trials of Patients with Multiple Myeloma: A Systematic Literature Review of Studies Published Between 2014 and 2021. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 442-459. | 0.4 | 7 |
| 8 | Investigating Trends in the Quality of Reporting of Patient-Reported Outcomes in Oncology Over Time: Analysis of 631 Randomized Controlled Trials Published Between 2004 and 2019. <i>Value in Health</i> , 2021, 24, 1715-1719. | 0.3 | 6 |
| 9 | Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. <i>Expert Review of Hematology</i> , 2021, 14, 293-302. | 2.2 | 5 |
| 10 | Physicians' Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform. <i>Frontiers in Oncology</i> , 2022, 12, 826040. | 2.8 | 5 |
| 11 | Clinician-reported symptomatic adverse events in cancer trials: are they concordant with patient-reported outcomes?. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 279-288. | 1.4 | 4 |
| 12 | Inclusion of older patients with cancer in randomised controlled trials with patient-reported outcomes: a systematic review. <i>BMJ Supportive and Palliative Care</i> , 2019, 9, bmjspcare-2019-001902. | 1.6 | 4 |
| 13 | Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2021, 17, 307-314. | 1.2 | 4 |
| 14 | Patient-reported outcome assessment in acute leukemias: Moving beyond the barriers. <i>Cancer</i> , 2018, 124, 3066-3067. | 4.1 | 1 |
| 15 | Does the quality of patient-reported outcomes (PROs) assessment in randomized controlled trials (RCTs) differ across cancer types and over time? A pooled analysis of 610 RCTs published between 2004 and 2018.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18218-e18218. | 1.6 | 1 |
| 16 | Inclusion of patient-reported outcomes (PROs) in randomized controlled trials (RCTs) with elderly cancer patients: A systematic review.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18217-e18217. | 1.6 | 1 |
| 17 | PCN368 - CONCORDANCE BETWEEN PATIENTS AND CLINICIANS' REPORTING OF SYMPTOMATIC ADVERSE EVENTS IN CANCER CLINICAL TRIALS: A SYSTEMATIC REVIEW. <i>Value in Health</i> , 2018, 21, S76-S77. | 0.3 | 0 |